Elamipretide vs Omentin-1
Head-to-head comparison of Elamipretide (Elamipretide (MTP-131, SS-31)) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Elamipretide | Omentin-1 |
|---|---|---|
| Category | Muscle & Performance | Diabetes & Metabolic |
| Full Name | Elamipretide (MTP-131, SS-31) | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 639.8 Da | ~35 kDa |
| Half-Life | 1-4 hours | hours |
| Amino Acids | 4 | 313 |
| Typical Dose | 0.01-0.25 mg/kg/day | No approved human dose; research use only |
| Route | Subcutaneous/Intravenous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 120 | 82 |
| Research Status | Clinical | Pre-clinical |
Elamipretide Benefits
- ✓mitochondrial protection
- ✓reduced oxidative stress
- ✓improved fatigue resistance
- ✓may support exercise tolerance
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Elamipretide Dosing
0.01-0.25 mg/kg/day SC (clinical research)|daily dosing in trials|alternative IV protocols in some studies
Omentin-1 Dosing
not established|not established
Elamipretide Side Effects
- ⚠nausea
- ⚠injection-site reactions
- ⚠diarrhea
- ⚠headache
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Elamipretide
Clinical and translational studies show elamipretide can improve mitochondrial function and some functional endpoints in mitochondrial disorders. Skeletal muscle research suggests benefits are driven by energy metabolism rather than direct muscle-building effects.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.